Basket | Login | Register

 
 
 
 

Latvia

2012: National Dementia Strategies (diagnosis, treatment and research)

Issues relating to medical treatment

The availability of medicines in general

Pharmaceutical drugs are reimbursed on the basis of the type, character and severity of diseases at either 100%, 75% or 50%. Those which are eligible for reimbursement are included on “the positive list” and further divided into three categories (A, B and C)[1]. List A contains clusters of interchangeable pharmaceutical products and the reference price for each cluster is that of the cheapest product based on the form, dosage and package size. List B contains products which are not interchangeable and List C contains products which are considered expensive (e.g. treatment exceeding LVL 3,000 (EUR 4,288) a year). The reimbursement of pharmaceuticals products is also possible if a person’s disease is not included in the list of diagnoses for which reimbursement would be possible but their life would be endangered without that particular drug. The reimbursement of pharmaceutical drugs cannot exceed LVL 10,000 (EUR 14,292) per person per 12 months.

The availability of Alzheimer treatments

All four AD drugs are available but none of them are part of the reimbursement system.

Conditions surrounding the prescription and reimbursement of AD drugs

Prescription and reimbursement

Donepezil

Rivastigmine

Galantamine

Memantine

Available

Yes

Yes

Yes

Yes

Reimbursed

No

No

No

No

Issues relating to research

Latvia is not involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) but is an Associate member of the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.

[1] European Commission (2012): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland: Comparative tables

 

 
 

Last Updated: Tuesday 14 May 2013

 

 
  • Acknowledgements

    The above information was published in the 2012 Dementia in Europe Yearbook as part of Alzheimer Europe's 2012 Work Plan which received funding from the European Union in the framework of the Health Programme. Alzheimer Europe gratefully acknowledges the support it has received from the Alzheimer Europe Foundation for the preparation and publication of its 2012 Yearbook.
  • European Union
 
 

Options